Skip to search formSkip to main contentSkip to account menu

umeclidinium

Known as: 1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane 
National Institutes of Health

Related topics

Related topics

8 relations
30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler30 ACTUAT umeclidinium 0.0625 MG/ACTUAT Dry Powder Inhaler [Incruse]7 ACTUAT umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhalerumeclidinium / vilanterol

Broader (1)

GSK573719

Narrower (2)

IncruseUMECLIDINIUM BROMIDE

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
2019
2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort…
Background and objective Retrospective claims data in patients with chronic obstructive pulmonary disease (COPD) initiating… 
2018
2018
Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA.
2017
2017
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
Introduction Patients with COPD who remain symptomatic on long-acting bronchodilator monotherapy may benefit from step-up therapy… 
Review
2016
Review
2016
Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting muscarinic antagonist [LAMA] plus a long… 
2016
2016
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study
Benefits of triple therapy with a long-acting muscarinic antagonist (LAMA), added to inhaled corticosteroid (ICS)/long-acting β2… 
2016
2016
Another Choice for Prevention of COPD Exacerbations.
Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines1 recommend either a long-acting beta-agonist (LABA) plus… 
2014
2014
Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
Background and objectivesA fixed-dose combination of the bronchodilators umeclidinium and vilanterol is in development for the… 
Review
2013
Review
2013
Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
Bronchodilators are central drugs in the management of patients with chronic obstructive pulmonary disease (COPD). Indacaterol… 
2012
2012
Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults
Introduction: Umeclidinium (UMEC; GSK573719) is a new, long-acting muscarinic antagonist in development for treatment of chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)